Which of the following potassium sparing diuretic alters cardiac moality-
## **Core Concept**
Potassium-sparing diuretics are a class of drugs that help the body get rid of excess fluid but minimize the loss of potassium. They are often used in the management of conditions like heart failure and hypertension. The question focuses on their impact on cardiac mortality.
## **Why the Correct Answer is Right**
Spironolactone, a potassium-sparing diuretic, has been shown to have a significant impact on cardiac mortality. It acts as an aldosterone antagonist, which is particularly beneficial in patients with heart failure. The RALES trial (Randomized Aldactone Evaluation Study) demonstrated that spironolactone significantly reduced the risk of both morbidity and mortality in patients with severe heart failure. This effect is attributed to its ability to counteract the harmful effects of aldosterone on the heart, including fibrosis and remodeling.
## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because while it might represent a potassium-sparing diuretic, its specific effect on cardiac mortality compared to spironolactone is not as well established or as significant.
- **Option B:** This is incorrect because, similar to Option A, its impact on cardiac mortality is not as pronounced or as well documented as spironolactone.
- **Option D:** This option is incorrect because it does not represent a drug that has been specifically highlighted for altering cardiac mortality in the context of potassium-sparing diuretics.
## **Clinical Pearl / High-Yield Fact**
A key point to remember is that spironolactone is not only a potassium-sparing diuretic but also has a significant role in reducing mortality in heart failure patients, making it a critical drug in the management of heart failure, especially in patients with severe symptoms.
## **Correct Answer:** . Spironolactone